Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Mar 05, 2024 11:30am
189 Views
Post# 35915841

On going Goblet next arm

On going Goblet next arm

The announced formalization of next goblet arm & the strong wording from the various project oversight people, is good news.
It shows on - going commitment & trust in Pelareorep.
The FOLFIRINOX, co- therapy arm, could be interesting?
I do not belive it is held by any individual pharma , as it is if itself a combination of 4 various treatments.
Folirinox is also highly toxic , as are many chemo drugs & combinations.
So that aspect could be concerning. 
We have heard mutiple times Pela is safe & well tolerated. Some mimic that statement. Yet! Is very important.
I know cancer & I know chemo. In some situations, the treatment is more damaging than the cancer.
The hard part is killing only cancer cells.
Pela only replicates in cancer cells. 

Yes today is good news. As s continued endorsement to oncolytics biotech & Pela.
What is missing is the all important $$$ piece of the puzzle.
Another potential use for Pela is great. They do however need $ to moving into phase 3.
partneship, buyout or other.
I dont think Thursday will be anything groundbreaking.
However , they need answers, either before ( tomorrow'), or very soon after.
The analysts will be giving updated projections based on what they know to be true & expectations of future income & various times.
With Onc anything is possible.
stay tuned
 

<< Previous
Bullboard Posts
Next >>